Cytogenetic abnormalities of tumor-associated endothelial cells in human malignant tumors

American Journal of Pathology

Volumn 175, Issue 6, 2009, Pages 2657-2667

  Akino, Tomoshige ^a,b   Hida, Kyoko ^a   Hida, Yasuhiro ^b   Tsuchiya, Kunihiko ^a,b   Freedman, Deborah ^c,d   Muraki, Chikara ^a   Ohga, Noritaka ^a   Matsuda, Kouhei ^a   Akiyama, Kousuke ^a   Harabayashi, Toru ^b   Shinohara, Nobuo ^b   Nonomura, Katsuya ^b   Klagsbrun, Michael ^c   Shindoh, Masanobu ^a  

^a HOKKAIDO UNIVERSITY   (Japan)

^b HOKKAIDO UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^c BOSTON CHILDREN S HOSPITAL   (United States)

^d FOX CHASE CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CD133 ANTIGEN;

ADULT; AGED; ANEUPLOIDY; ANIMAL CELL; ARTICLE; CELL CULTURE; CHROMOSOME 7; CHROMOSOME 8; CHROMOSOME ANALYSIS; CONTROLLED STUDY; DIPLOIDY; DNA PROBE; ENDOTHELIUM CELL; FEMALE; FLUORESCENCE IN SITU HYBRIDIZATION; HUMAN; HUMAN TISSUE; KIDNEY CARCINOMA; MALE; MALIGNANT NEOPLASTIC DISEASE; MOUSE; NONHUMAN; PRIORITY JOURNAL; STROMA; TUMOR CELL; XENOGRAFT;

EID: 73549104498     PISSN: 00029440     EISSN: 15252191     Source Type: Journal    
DOI: 10.2353/ajpath.2009.090202     Document Type: Article

References (37)

1. Folkman J: Angiogenesis in cancer, vascular, rheumatoid and other disease. Nat Med 1995, 1:27-31
2. Hurwitz H, Fehrenbacher L, Novotny W, Cartwright T, Hainsworth J, Heim W, Berlin J, Baron A, Griffing S, Holmgren E, Ferrara N, Fyfe G, Rogers B, Ross R, Kabbinavar F: Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 2004, 350:2335-2342
3. Miller KD, Chap LI, Holmes FA, Cobleigh MA, Marcom PK, Fehrenbacher L, Dickler M, Overmoyer BA, Reimann JD, Sing AP, Langmuir V, Rugo HS: Randomized phase III trial of capecitabine compared with bevacizumab plus capecitabine in patients with previously treated metastatic breast cancer. J Clin Oncol 2005, 23:792-799
4. Escudier B, Pluzanska A, Koralewski P, Ravaud A, Bracarda S, Szczylik C, Chevreau C, Filipek M, Melichar B, Bajetta E, Gorbunova V, Bay JO, Bodrogi I, Jagiello-Gruszfeld A, Moore N: Bevacizumab plus interferon α-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trial. Lancet 2007, 370:2103-2111
5. Folkman J: Angiogenesis: an organizing principle for drug discovery? Nat Rev Drug Discov 2007, 6:273-286
6. Folkman J: Tumor angiogenesis: therapeutic implications. N Engl J Med 1971, 285:1182-1186
7. Allinen M, Beroukhim R, Cai L, Brennan C, Lahti-Domenici J, Huang H, Porter D, Hu M, Chin L, Richardson A, Schnitt S, Sellers WR, Polyak K: Molecular characterization of the tumor microenvironment in breast cancer. Cancer Cell 2004, 6:17-32
8. Lu C, Bonome T, Li Y, Kamat AA, Han LY, Schmandt R, Coleman RL, Gershenson DM, Jaffe RB, Birrer MJ, Sood AK: Gene alterations identified by expression profiling in tumor-associated endothelial cells from invasive ovarian carcinoma. Cancer Res 2007, 67:1757-1768
9. McDonald DM, Choyke PL: Imaging of angiogenesis: from microscope to clinic. Nat Med 2003, 9:713-725
10. Seaman S, Stevens J, Yang MY, Logsdon D, Graff-Cherry C, St. Croix B: Genes that distinguish physiological and pathological angiogenesis. Cancer Cell 2007, 11:539-554
11. St Croix B, Rago C, Velculescu V, Traverso G, Romans KE, Montgomery E, Lal A, Riggins GJ, Lengauer C, Vogelstein B, Kinzler KW: Genes expressed in human tumor endothelium. Science 2000, 289:1197-1202
12. Streubel B, Chott A, Huber D, Exner M, Jager U, Wagner O, Schwarzinger I: Lymphoma-specific genetic aberrations in microvascular endothelial cells in B cell lymphomas. N Engl J Med 2004, 351:250-259
13. Bussolati B, Deambrosis I, Russo S, Deregibus MC, Camussi G: Altered angiogenesis and survival in human tumor-derived endothelial cells. FASEB J 2003, 17:1159-1161
14. Gunsilius E, Duba HC, Petzer AL, Kahler CM, Grunewald K, Stockhammer G, Gabl C, Dirnhofer S, Clausen J, Gastl G: Evidence from a leukaemia model for maintenance of vascular endothelium by bonemarrow-derived endothelial cells. Lancet 2000, 355:1688-1691
15. Hida K, Hida Y, Amin DN, Flint AF, Panigrahy D, Morton CC, Klagsbrun M: Tumor-associated endothelial cells with cytogenetic abnormalities. Cancer Res 2004, 64:8249-8255
16. Hida K, Klagsbrun M: A new perspective on tumor endothelial cells: unexpected chromosome and centrosome abnormalities. Cancer Res 2005, 65:2507-2510
17. Arbiser JL, Raab G, Rohan RM, Paul S, Hirschi K, Flynn E, Price ER, Fisher DE, Cohen C, Klagsbrun M: Isolation of mouse stromal cells associated with a human tumor using differential diphtheria toxin sensitivity. Am J Pathol 1999, 155:723-729
18. Gussoni E, Wang Y, Fraefel C, Miller RG, Blau HM, Geller AI, Kunkel LM: A method to codetect introduced genes and their products in gene therapy protocols. Nature Biotechnol 1996, 14:1012-1016
19. Liao SY, Aurelio ON, Jan K, Zavada J, Stanbridge EJ: Identification of the MN/CA9 protein as a reliable diagnostic biomarker of clear cell carcinoma of the kidney. Cancer Res 1997, 57:2827-2831
20. Jacobsen BM, Harrell JC, Jedlicka P, Borges VF, Varella-Garcia M, Horwitz KB: Spontaneous fusion with, and transformation of mouse stroma by, malignant human breast cancer epithelium. Cancer Res 2006, 66:8274-8279
21. Weaver BA, Silk AD, Montagna C, Verdier-Pinard P, Cleveland DW: Aneuploidy acts both oncogenically and as a tumor suppressor. Cancer Cell 2007, 11:25-36
22. Asahara T, Murohara T, Sullivan A, Silver M, van der Zee R, Li T, Witzenbichler B, Schatteman G, Isner JM: Isolation of putative progenitor endothelial cells for angiogenesis. Science 1997, 275:964-967
23. Lyden D, Hattori K, Dias S, Costa C, Blaikie P, Butros L, Chadburn A, Heissig B, Marks W, Witte L, Wu Y, Hicklin D, Zhu Z, Hackett NR, Crystal RG, Moore MA, Hajjar KA, Manova K, Benezra R, Rafii S: Impaired recruitment of bone-marrow-derived endothelial and hematopoietic precursor cells blocks tumor angiogenesis and growth. Nat Med 2001, 7:1194-1201
24. Rafii S, Lyden D, Benezra R, Hattori K, Heissig B: Vascular and haematopoietic stem cells: novel targets for anti-angiogenesis therapy? Nat Rev Cancer 2002, 2:826-835
25. Gehling UM, Ergun S, Schumacher U, Wagener C, Pantel K, Otte M, Schuch G, Schafhausen P, Mende T, Kilic N, Kluge K, Schafer B, Hossfeld DK, Fiedler W: In vitro differentiation of endothelial cells from AC133-positive progenitor cells. Blood 2000, 95:3106-3112
26. Yin AH, Miraglia S, Zanjani ED, Almeida-Porada G, Ogawa M, Leary AG, Olweus J, Kearney J, Buck DW: AC133, a novel marker for human hematopoietic stem and progenitor cells. Blood 1997, 90: 5002-5012
27. Damelin M, Sun YE, Sodja VB, Bestor TH: Decatenation checkpoint deficiency in stem and progenitor cells. Cancer Cell 2005, 8:479-484
28. Kops GJ, Weaver BA, Cleveland DW: On the road to cancer: aneuploidy and the mitotic checkpoint. Nat Rev Cancer 2005, 5:773-785
29. Amin DN, Hida K, Bielenberg DR, Klagsbrun M: Tumor endothelial cells express epidermal growth factor receptor (EGFR) but not ErbB3 and are responsive to EGF and to EGFR kinase inhibitors. Cancer Res 2006, 66:2173-2180
30. Wang JH, Wu QD, Bouchier-Hayes D, Redmond HP: Hypoxia upregulates Bcl-2 expression and suppresses interferon γ induced antiangiogenic activity in human tumor derived endothelial cells. Cancer 2002, 94:2745-2755
31. Grange C, Bussolati B, Bruno S, Fonsato V, Sapino A, Camussi G: Isolation and characterization of human breast tumor-derived endothelial cells. Oncol Rep 2006, 15:381-386
32. Ferrara N, Kerbel RS: Angiogenesis as a therapeutic target. Nature 2005, 438:967-974
33. Kerbel RS, Yu J, Tran J, Man S, Viloria-Petit A, Klement G, Coomber BL, Rak J: Possible mechanisms of acquired resistance to antiangiogenic drugs: implications for the use of combination therapy approaches. Cancer Metastasis Rev 2001, 20:79-86
34. Shekhar MP, Werdell J, Santner SJ, Pauley RJ, Tait L: Breast stroma plays a dominant regulatory role in breast epithelial growth and differentiation: implications for tumor development and progression. Cancer Res 2001, 61:1320-1326
35. Mueller MM, Fusenig NE: Tumor-stroma interactions directing phenotype and progression of epithelial skin tumor cells. Differentiation 2002, 70:486-497
36. Fukino K, Shen L, Patocs A, Mutter GL, Eng C: Genomic instability within tumor stroma and clinicopathological characteristics of sporadic primary invasive breast carcinoma. J Am Med Assoc 2007, 297:2103-2111
37. Zalcman G, Bergot E, Hainaut P: Breast-cancer stromal cells with TP53 mutations. N Engl J Med 2008, 358:1635-1636; author reply 1636